LATEST MANUSCRIPTS IN International Journal of Hematologic Oncology
Omer S Ashruf, Saeid Mirzai, Laeth L George, Faiz Anwer. Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.International journal of hematologic oncology. 2023, 12 (2): IJH44
Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf. Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia.International journal of hematologic oncology. 2023, 12 (1): IJH42
Ahmed Alnughmush, Riad El Fakih, Shamayel Mohammed, Mahmoud Aljurf. Pediatric-type follicular lymphoma: a short review.International journal of hematologic oncology. 2022, 11 (4): IJH41
Maroun Bou Zerdan, Lewis Nasr, Joseph Kassab, Ludovic Saba, Myriam Ghossein, Marita Yaghi, Barbara Dominguez, Chakra P Chaulagain. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.International journal of hematologic oncology. 2022, 11 (2): IJH39
Guray Saydam, Ridvan Ali, Ahmet Muzaffer Demir, Ahmet Emre Eskazan, Birol Guvenc, Ibrahim Celalettin Haznedaroglu, Mehmet Ali Ozcan, Ozan Salim, Mehmet Sonmez, Ayse Tulin Tuglular, Mehmet Turgut, Ali Unal, Birkan Aver, Sirac Bozkurt, Begum Ozdengulsun, Osman Ilhan. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.International journal of hematologic oncology. 2022, 11 (1): IJH38
Istemi Serin, Mehmet Hilmi Dogu. The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.International journal of hematologic oncology. 2021, 10 (4): IJH37
Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti. A Phase I trial of talazoparib in patients with advanced hematologic malignancies.International journal of hematologic oncology. 2021, 10 (3): IJH35
Osman Yokus, Celalettin Herek, Tahir Alper Cinli, Hasan Goze, Istemi Serin. Iron overload during the treatment of acute leukemia: pretransplant transfusion experience.International journal of hematologic oncology. 2021, 10 (3): IJH36
Julio C Chavez, Farah Yassine, Jose Sandoval-Sus, Mohamed A Kharfan-Dabaja. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.International journal of hematologic oncology. 2021, 10 (2): IJH33
Srinivas Devarakonda, Yogesh Jethava. Minimal residual disease in multiple myeloma: are we there yet?International journal of hematologic oncology. 2020, 9 (4): IJH29
Stefano Molica. Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia.International journal of hematologic oncology. 2020, 9 (4): IJH31
Garrick Edouard Laudin, Peter F Levay, Buks Coetzer. Globulin fraction and albumin: globulin ratio as a predictor of mortality in a South African multiple myeloma cohort.International journal of hematologic oncology. 2020, 9 (3): IJH27